Gaurao is an MBA from Wales university and an engineering graduate from Mumbai university. He is involved in international trade and has been passionately tracking global equity markets for more than 7 years. He has been focusing mainly on spotting long term value investments in biotechnology, pharmaceutical, health insurance, hospital, and medical device sectors.
I keep my profile anonymous because I want my brand to be the content and strength of my arguments and thoughts. In my opinion, too much focus with financial research is put on reputation and pedigree, which is a form of herd-following if you think about it.
Real investment success and insight is obtained through independent thinking and the willingness to invest when others aren't.
For that reason, I believe the focus should be an objective analysis made without emotions, acknowledging the strengths and weaknesses of your arguments to the point that you are aware of them.
Get the highest conviction investment ideas from the world's greatest ideas for $12 per month. The Superinvestor Bulletin builds a portfolio exclusively from the highest conviction investments made by the world’s greatest investors. Since the world’s greatest investors tend to return 15 to 20 percent per year on average, replicating their best ideas should provide superior returns (without their egregious performance fees).Two full investment ideas per month (15 to 20 page report) plus weekly updates. Visit our website or contact us directly for a free sample report.
I've been investing for over 40 years. On my 18th birthday, I bought Continental Airlines, which immediately dropped and four months later I sold it for a 10% profit, foreshadowing many future trading experiences. I got burned in the dot-com bubble and swore off investing. I did some calculations and discovered if I put my investing money into my mortgage, that would be the best ROI and I'd recoup all my dot-com losses, so I did it and paid my house off early. I missed the 2008 Bear Market, after having been burned in the dot-com bubble, but followed the market every day since I was 14 when I paid for a WSJ subscription from profits from my paper route. I doubled my money in 2013 in the stock market. I doubled my money again in 2014. 2015 has been quite a bit tougher, and I have become more cautious and more research intensive. I have flipped stocks several times a day and I have held stocks for years, too. Overall, I made nice profits with stocks, but only broke even buying and selling options. Never traded commodities or shorted stocks. Never say never. Researching companies keeps me abreast of all the latest technological advancements and it is really cool to know about all of that.
Rising junior in the School of Foreign Service at Georgetown University. Majoring in International Political Economics and International Business Diplomacy. Interested in macro trends and contrarian investing.
Anita Dushyanth is a Biotechnology Technology and Medical Devices Analyst with Zacks Investment Research.
She has worked as a researcher in the field of Bioengineering at the University of California, Los Angeles (UCLA) for over 10 years. Her expertise includes research that delves into the biomechanics of the human body, degenerative disease progression, quantitative image analysis and optimization, and design and development of medical compliant devices. She has published and presented several research articles and has also been a peer reviewer and an editor for a number of prestigious journals in the field of biomedical engineering. Prior to that, Anita worked as a researcher at the Department of Radiology and Biomedical Imaging at the University of California, San Francisco (UCSF).
Anita holds a PhD degree in Bioengineering from UCLA, M.S. in Biomedical Engineering from Wright State University, Dayton, OH and B.S. in Instrumentation Engineering from the University of Madras, India.
I am individual investor with over 35 years investing experience. I have traded almost everything you can over that time. I prefer investing in microcaps as there can be above average rewards along with higher risk. The areas I follow very closely are: Technology, Intellectual Property, Precious Metals, Rare Earths, mining companies and Biotechs. Picking the emerging leaders can provide huge rewards for early investors. I blog on topics that are of interest to me and on ones that I hope will generate good discussion. I don’t consider myself an expert in any one area, but know a little about a lot of things. I believe as soon as we stop learning, we stop living.
I am also a guest contributor to the Patent Stock Review, the most comprehensive investment research and news aggregation service on Wall Street, covering publicly traded companies seeking to monetize their IP portfolios, or "Patent Play Stocks."
That's what I would like to bring across more than anything. I am not a professional trader/investor. I am not even remotely wealthy. I can not make you rich. I have made some money in short term trading and I have lost some money doing the same. Short term trading has been a wash for me as any profits taken were quickly usurped by idiotic losses.
Why? Because I rushed in to trading in companies that I knew next to nothing about. Maybe I saw a newsletter. Maybe a friend mentioned something. However it happened, in retrospect, it was the wrong reason to invest. It sure felt good when a trade was a winner, but I'd take those profits and either try and chase, or would invest in a stinker immediately afterwards.
Through it all though, I have maintained several stocks that I was long out of the gate on, because I saw potential when I studied the companies. These were companies that I saw as having massive upside with minimal risk. Consequently, I invested more in these longs than I ever risked on the short term plays.
These are the stocks that I would like to write about, as I feel they are worth my time to write about.
Everything I write is, of course, my opinion, and in no way should be taken as investment advice.
I am going to write and I don't care if you read it.
I am an individual and occasional investor with a passion for biotechnology and stocks. I am working as an engineer with ties to the healthcare sector.
I build investment theses based on thorough personal research and end up picking only stocks that I think hold a very high and long-term potential. I specialize in micro-cap and/or European biotechs, tracking undervalued opportunities and basing my investment choices on the deep analysis of a company's fundamentals and its long-term perspective (at least several years).
Follow me on twitter: https://twitter.com/Logribel
Editor for The Biotech Forum (www.biotechforumsa.com), the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade. For Free weekly investment reports on small, attractive biotech stocks just register at www.bretjenseninvests.com
I am an Senior Biotech Analyst with Zacks Investment Research, Inc. I joined Zacks in February 2014.
Prior to joining Zacks, I was an NRSA Postdoctoral Fellow working in a cancer genetics laboratory.
I received my PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. I also have my BS and MS in Biochemistry from Virginia Tech.
I'm an investor focused on IP situations, and have invested in the market for countless years. Past employment has been in the investment banking, venture capital, and hedge fund spaces. I currently work in corporate development and invest my excess capital in my spare time.
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science.
Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity.
Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering.
With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.
I am an individual investor who has been actively involved in the healthcare and biotechnology space for over 15 years. I hold a PhD in the biomedical sciences and have worked in both large pharmaceutical and small biotech companies. I make investments based on the fundamentals of a company and if I believe they have a superior technology or products compared to the competition. I'm an investor who believes patience pays off.
Consultant / Investment research writer, focusing on natural resource companies & select other small cap opportunities. MBA, Financial Analysis, Top 12 rated business school, New York University (NYU) Stern School of Business.
Designated a Chartered Financial Analyst, "CFA" He's published hundreds of investment articles & CEO interviews on a number of prominent [Metals & Mining] and [Investment] websites including:
EpsteinResearch, InvestorIdeas, InvestingNews, MiningFeeds, Equity.Guru, Investing.com, Equities.com, CNAFinance, CountingPips, StockHouse, SeekingAlpha, TalkMarkets, CEO.CA, Investor-SMS.de, SmallCapMarkets.
On Twitter: @peterepstein2 Email: firstname.lastname@example.org